Presented in part as a poster at the American Society of Cataract and Refractive Surgeons (ASCRS) Symposium in Philadelphia, PA, USA, 1−5 June 2002.
Randomized clinical trial of the efficacy and safety of tropicamide and phenylephrine in preoperative mydriasis for phacoemulsification
Article first published online: 12 FEB 2003
Clinical & Experimental Ophthalmology
Volume 31, Issue 1, pages 52–56, February 2003
How to Cite
Lam, P. T., Poon, B. T., Wu, W.-K., Chi, S. C. and Lam, D. S. (2003), Randomized clinical trial of the efficacy and safety of tropicamide and phenylephrine in preoperative mydriasis for phacoemulsification. Clinical & Experimental Ophthalmology, 31: 52–56. doi: 10.1046/j.1442-9071.2003.00600.x
- Issue published online: 12 FEB 2003
- Article first published online: 12 FEB 2003
Purpose: To compare the mydriatic effect and safety between different concentrations of tropicamide and phenylephrine in preoperative mydriasis for phacoemulsification.
Methods: Two hundred and seventeen consecutive eyes in the same number of Chinese patients undergoing phacoemulsification under local or topical anaesthesia in a university-based eye hospital were analyzed. Patients were randomized into two groups by cluster randomization, each group receiving a different preoperative mydriatic regimen. Regimen A consisted of tropicamide 1.0% with phenylephrine 2.5%, and Regimen B consisted of tropicamide 0.5% with phenylephrine 0.5%. The main outcome measures were horizontal pupillary diameter, systolic, diastolic and pulse pressure and pulse rate.
Results: The group who received Regimen A attained a mean horizontal pupillary diameter of 7.00 ± 1.06 mm. Their pupils were significantly larger than those receiving Regimen B (6.61 ± 1.03 mm, P = 0.007). No untoward cardiovascular effects were noted in either groups.
Conclusion: Regimen A attained better preoperative mydriasis for phacoemulsification than Regimen B. Both regimens were safe with regard to their cardiovascular effects. The combination of tropicamide 1.0% and phenylephrine 2.5% is recommended as preoperative mydriatic for phacoemulsification in Chinese patients who have darkly pigmented irides.